Silverback Therapeutics Stock News

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer, will participate in pres...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Justin Chakma - CBO Richard Lowenthal - Co-Founder, President and CEO Eric Karas - CCO Kathleen Scott - CFO Conference Call Participants Ryan Deschner - Raymond James Josh Schimmer - Cantor Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Andreas Argyrides -...

$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, n...

The availability of neffy 1 mg extends protection to younger, school-aged children—who make up nearly 23% of people needing epinephrine Visit neffy.com for savings and support programs and pay as little as $25 (if eligible) in preparation for summer travel and back-to-school SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicat...

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m.

Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United Kingdom, European Union and certain other countries outside the United States

ARS Pharmaceuticals has a recently launched needle-free epinephrine product for allergic reactions, neffy, and strong cash reserves. The company targets a ~$3B+ U.S. market, geographic expansion and intends to also address acute flares in chronic spontaneous urticaria. Financial projections include $500M peak U.S. sales, $500M outside the U.S., and $150M for chronic spontaneous urticaria, with ...

ARS Pharmaceuticals, Inc.'s stock surged 25% today after strong Q4 and full-year 2024 earnings, driven by the needle-free epinephrine treatment, neffy, which has promising market potential. Neffy's competitive edge lies in its innovative intranasal delivery, targeting a $3 billion initial addressable market in the U.S. with potential growth prospects. Despite neffy's potential, risks include co...